Pharma

Pharma

Immuno-oncology drugs and agents with novel MoAs to further influence treatment paradigms in cancer indications in 2020, says GlobalData

As 2020 commences for the pharmaceutical industry, Fern Barkalow, PhD, Senior Director of Oncology and Hematology, as well as members of her analyst team at leading data and analytics company GlobalData comment on some of the key trends that will continue to influence clinical development in both solid tumors and hematological cancers in 2020, including […]

Pharma

Mesoblast’s stem cell candidate for chronic low back pain expected to have market access challenges, says GlobalData

In the search for non-opioid options to treat pain, Mesoblast has turned to a stem cell approach, which is currently in late-stage development for chronic low back pain. However, interviewed experts say its potential for Phase III success is uncertain due to scant human evidence with this stem cell product for treating pain. Even if […]

Pharma

NRDL a promising sign for increased market access to innovative drugs in China, says GlobalData

In November 2019, China updated its National Reimbursement Drug List (NRDL) to include 70 new medicines, with an average price cut of 61% agreed by pharma companies. This a promising opportunity for innovative drug manufacturers to foray into the second largest pharmaceutical market in the world after the US in terms of value, says GlobalData, […]

Pharma

HIV first-in-class pipeline sees high levels of innovation that targets drug resistance and latency reversal

The human immunodeficiency virus (HIV) pipeline is robust, with 450 products in active development that display a high degree of novelty and diversity. Promisingly, there are 87 first-in-class products that act on a range of 50 molecular targets, which can broadly be classified as host or viral factors, indicating a high level of innovation in comparison with the marketed products, says GlobalData, a leading data and analytics company. The company’s recent report, ‘HIV: First-in-Class Therapies Target Major Unmet Needs Including Drug Resistance and Latency Reversal’, reveals that the majority of the 10 highest-ranking targets have […]

Pharma

China can use lessons they learned from SARS outbreak to tackle new Wuhan coronavirus, says GlobalData

Following the news that cases of people infected with the Wuhan coronavirus rose to more than 270 laboratory-confirmed cases and the virus may spread from human-to-human; Philipp Rosenbaum, Infectious Diseases Analyst at GlobalData, a leading data and analytics company, provides his view: “China has experience with this kind of viral outbreak. The new coronavirus 2019-nCoV […]

Pharma

Key trends that will shaped the immunology market in the last decade, according to GlobalData

From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry. Patrick Aiyes, Senior Immunology Analyst at leading data and analytics company GlobalData, observes the key trends that has shaped the immunology market in the last decade: Key immunology drugs “The immunology […]

Pharma

Antibiotic stewardship programs a double-edged sword for tackling sepsis, says GlobalData

News earlier this week highlighted that new data have emerged suggesting that sepsis is a bigger killer than cancer. Sepsis has proven to be deadly, but perhaps its most pernicious aspect is that it results from myriad factors, including uncontrolled infection and inflammatory processes across multiple organs. Experts interviewed by data and analytics company GlobalData routinely […]

Pharma

7MM to see sepsis cases grow to 3.1 million by 2026, says GlobalData

Following the news that sepsis has been found to be a bigger killer than cancer worldwide in a study by Rudd et al; Kasey Fu, Director of Epidemiology at GlobalData, provides her view: “The *7MM will see diagnosed incident cases of sepsis grow at an annual growth rate (AGR) of 2.06% per year over the […]

Pharma

Immuno-oncology and personalized medicine will continue to drive the pharmaceutical industry in 2020

Nearly three quarters of global industry stakeholders identified immuno-oncology (I-O) or personalized medicine as the most impactful trends that will shape the pharmaceutical sector in 2020, says GlobalData, a leading data and analytics company. Claire Herman, Global Director of Therapy Analysis and Epidemiology at GlobalData, comments: “For the second consecutive year, our survey found that […]

Pharma

Heart failure market to surpass $22bn by 2028 as arrival of SGLT inhibitors triggers huge growth

The heart failure (HF) market is expected to grow from $3.7bn in 2018 to $22.1bn in 2028 across the eight major markets (8MM*) at an impressive compound annual growth rate (CAGR) of 19.5%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Heart Failure: Global Drug Forecast and Market Analysis to […]

Pharma

Biosimilars will contribute to cost-savings in US pharmaceutical industry in 2020

The pharmaceutical industry is mixed on the factors that will have the greatest positive impact on the industry in 2020, with patent expiry of biologics and vertical integration highlighted as some of the key areas of interest, says leading data and analytics company, GlobalData. According to the company’s latest annual outlook report, ‘The State of the Biopharmaceutical Industry – 2020’, about 20% of survey respondents respectively identified patent expiry of biologics and vertical integration […]

Pharma

Pricing and reimbursement concern to remain the leading impediment to industry growth in 2020

In 2020, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData, a leading data and analytics company. The company’s latest annual outlook report, ‘The State of the Biopharmaceutical Industry – 2020’, reveals that 49% of global industry survey respondents believe that […]

Pharma

Seasonal influenza vaccine market across China, India and Japan set to reach US$1bn by 2028, says GlobalData

The size of the seasonal influenza vaccine market across the three major Asia-Pacific (APAC) growth markets (3GM*) will grow at a modest compound annual growth rate (CAGR) of 1.4% from US$914m in 2018 to US$1.05bn in 2028, says GlobalData, a leading data and analytics company. The company’s latest report, ‘Seasonal Influenza: Forecast in Asia-Pacific Markets […]

Pharma

Functional links between metabolic, cardiovascular and renal diseases, as well as focus on digital and personalized approach to shape diabetes drug development in 2020, says GlobalData

As 2019 draws to a close, Valentina Gburcik, PhD, Senior Director of Cardiovascular and Metabolic Disorders, as well as Gender Health and Digital Teams at leading data and analytics company GlobalData, looks at the key trends that will shape the metabolic disorders pharmaceutical space in 2020, focusing on the most prevalent metabolic disorder of all, […]

Pharma, Press Release

Multiple sclerosis market to reach $32.9bn in 2028 driven by launch of pipeline agents

The multiple sclerosis (MS) therapeutics market has entered an exciting phase, with an upsurge of available treatment options and several promising late-stage pipeline products offering diverse mechanisms of action (MOA). The MS market is expected to grow in sales from $19.8bn in 2018 to $32.9bn in 2028 with a compound annual growth rate (CAGR) of […]

Pharma

Pharma executives have faith in AI to solve the R&D optimization puzzle, says GlobalData

The global pharmaceutical industry spends a significant amount of revenue on research and development (R&D) activities that are failing to deliver projected returns. A recent survey by GlobalData, a leading data and analytics company, has revealed that digital transformation with artificial intelligence (AI) at the forefront is seen as a major step forward towards enhancing […]

Pharma

Diagnosed prevalent cases of chronic heart failure to reach 32 million by 2028 in the 8MM, says GlobalData

Nearly 40% of all diagnosed prevalent cases of Chronic Heart Failure (CHF) in the eight major markets (8MM*) occur in the elderly population, and this is estimated to increase by a further 40% by 2028. The major drivers for this trend include increasing life expectancy, early diagnosis of heart failure (HF) by improved screening and […]

Pharma

Spinal muscular atrophy market across five growth markets in APAC will reach US$2.5bn in 2028, says GlobalData

The spinal muscular atrophy (SMA) market across the five growth markets ((5GM) Australia, China, India, Japan and South Korea) in the Asia-Pacific (APAC) region is anticipated to grow at a compound annual growth rate of 23.3% from US$308.6m in 2018 to US$2.5bn in 2028, says GlobalData, a leading data and analytics company. According to the […]

Pharma

UHC Act, regulatory tax reforms will open new opportunities for Indian pharma industry in Philippines, says GlobalData

The introduction of the Universal Health Care (UHC) Act coupled with business and corporate tax regulatory reforms in the Philippines is likely to open up new avenues for the Indian pharma industry, says GlobalData, a leading data and analytics company. GlobalData’s report, ‘CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Philippines’, reveals that the pharmaceutical market […]

Pharma

Axial spondyloarthritis burden in five APAC markets set to increase by 32.3% over next decade, says GlobalData

The diagnosed prevalent cases of axial spondyloarthritis (AxSpA) are expected to increase from 6.1 million cases in 2018 to 8.0 million cases in 2028, at an annual growth rate (AGR) of 3.23% across the five growth markets (*5GM: Australia, China [urban], India, South Korea and Japan) in the Asia-Pacific (APAC) region, according to GlobalData, a […]

Prev 1 … 103 104 105 106 107 … 110 Next

Immuno-oncology drugs and agents with novel MoAs to further influence treatment paradigms in cancer indications in 2020, says GlobalData

Mesoblast’s stem cell candidate for chronic low back pain expected to have market access challenges, says GlobalData

NRDL a promising sign for increased market access to innovative drugs in China, says GlobalData

HIV first-in-class pipeline sees high levels of innovation that targets drug resistance and latency reversal

China can use lessons they learned from SARS outbreak to tackle new Wuhan coronavirus, says GlobalData

Key trends that will shaped the immunology market in the last decade, according to GlobalData

Antibiotic stewardship programs a double-edged sword for tackling sepsis, says GlobalData

7MM to see sepsis cases grow to 3.1 million by 2026, says GlobalData

Immuno-oncology and personalized medicine will continue to drive the pharmaceutical industry in 2020

Heart failure market to surpass $22bn by 2028 as arrival of SGLT inhibitors triggers huge growth

Biosimilars will contribute to cost-savings in US pharmaceutical industry in 2020

Pricing and reimbursement concern to remain the leading impediment to industry growth in 2020

Seasonal influenza vaccine market across China, India and Japan set to reach US$1bn by 2028, says GlobalData

Functional links between metabolic, cardiovascular and renal diseases, as well as focus on digital and personalized approach to shape diabetes drug development in 2020, says GlobalData

Multiple sclerosis market to reach $32.9bn in 2028 driven by launch of pipeline agents

Pharma executives have faith in AI to solve the R&D optimization puzzle, says GlobalData

Diagnosed prevalent cases of chronic heart failure to reach 32 million by 2028 in the 8MM, says GlobalData

Spinal muscular atrophy market across five growth markets in APAC will reach US$2.5bn in 2028, says GlobalData

UHC Act, regulatory tax reforms will open new opportunities for Indian pharma industry in Philippines, says GlobalData

Axial spondyloarthritis burden in five APAC markets set to increase by 32.3% over next decade, says GlobalData

Browse

Company information